AFT Pharmaceuticals Limited expanded its co-operation with Hikma Pharmaceuticals to extend its license for Maxigesic/Combogesic IV, the intravenous form of the pain relief medicine, to Saudi Arabia, Iraq, and Jordan. Hikma is the licensee of the medicine in the US where it was recently launched.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,913 GBX | +3.18% | +6.34% | +6.93% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.93% | 5.29B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- AFT Pharmaceuticals Limited Extends License for Maxigesic/Combogesic IV with Hikma Pharmaceuticals